Belimumab: differenze tra le versioni
Vai alla navigazione
Vai alla ricerca
Contenuto cancellato Contenuto aggiunto
ins.cn| |
→Note: ins. bibl. |
||
| Riga 53: | Riga 53: | ||
== Note == |
== Note == |
||
<references/> |
<references/> |
||
== Bibliografia == |
|||
* {{cite book|author=Frank Ashall|title=Le grandi scoperte scientifiche|url=http://books.google.com/books?id=GXsecqAh6MEC&pg=PA245|accessdate=|year=1999|publisher=Armando Editore|isbn=9788871449494|pages=245–}} |
|||
* {{cite book|author1=Abul K. Abbas|author2=Andrew H. Lichtman|author3=Shiv Pillai|title=Immunologia cellulare e molecolare|url=http://books.google.com/books?id=9SFm3nMO_gUC&pg=PA79|accessdate= |year=2010|publisher=Elsevier srl|isbn=9788821431760|pages=79–}} |
|||
* {{cite book|author1=Abul K. Abbas|author2=Andrew H. Lichtman|title=Le basi dell'immunologia|url=http://books.google.com/books?id=szHkdI9buskC&pg=PA70|accessdate|year=2006|publisher=Elsevier srl|isbn=9788885675858|pages=70–}} |
|||
* {{cite book|author1=Humphrey P. Rang|author2=M. Maureen Dale|author3=James M. Ritter|title=Farmacologia|url=http://books.google.com/books?id=HGcP_ip4SmgC&pg=PA778|accessdate|year=2008|publisher=Elsevier srl|isbn=9788821430237|pages=778–}} |
|||
* {{cite book|author=Enzo Fagiolo|title=Immunoematologia|url=http://books.google.com/books?id=ErRtMU7SKhkC&pg=PA16|accessdate=|year=2007|publisher=Mediserve s.r.l.|isbn=9788882041359|pages=16–}} |
|||
* {{cite book|author=Paolo Larizza|title=Trattato di medicina interna|url=http://books.google.com/books?id=Rt4_C55_Ls4C&pg=PA909|accessdate=|year=2005|publisher=PICCIN|isbn=9788829917211|pages=909–}} |
|||
* {{cite book|author=Angelo Sghirlanzoni|title=Terapia Delle Malattie Neurologiche|url=http://books.google.com/books?id=LCNUGXlL4FQC&pg=PA113|accessdate= |date=3 April 2010|publisher=Springer|isbn=9788847011199|pages=113–}} |
|||
* {{cite book|author=Thomas C. King|title=Patologia|url=http://books.google.com/books?id=1CgV-Td_I3oC&pg=PA156|accessdate= |year=2008|publisher=Elsevier srl|isbn=9788821430190|pages=156–}} |
|||
* {{en}}{{cite book|author=Marie A. Simmons|title=Monoclonal antibodies: new research|url=http://books.google.com/books?id=jxhKskARw6IC|accessdate=|year=2005|publisher=Nova Publishers|isbn=9781594542473}} |
|||
* {{en}}{{cite book|author=Zhiqiang An|title=Therapeutic Monoclonal Antibodies: From Bench to Clinic|url=http://books.google.com/books?id=agdx2rtK7E0C|accessdate= |date=8 September 2009|publisher=John Wiley and Sons|isbn=9780470117910}} |
|||
* {{en}}{{cite book|author=James W. Goding|title=Monoclonal antibodies: principles and practice : production and application of monoclonal antibodies in cell biology, biochemistry and immunology|url=http://books.google.com/books?id=jPk4ZY4CnQQC|accessdate=|year=1996|publisher=Academic Press|isbn=9780122870231}} |
|||
* {{en}}{{cite book|author=Steve Shire|title=Current Trends in Monoclonal Antibody Development and Manufacturing|url=http://books.google.com/books?id=YTbJpdPhgT4C|accessdate= |date=April 2009|publisher=Springer|isbn=9780387766423}} |
|||
=== Belimumab === |
|||
* {{en}}{{cite book|author=Michael P. Cancro|title=BLyS Ligands and Receptors|url=http://books.google.com/books?id=Ai84m1_LFA8C&pg=PA178|accessdate |year=2010|publisher=Springer|isbn=9781603270120|pages=178–}} |
|||
* {{en}}{{cite book|author=Iqbal S. Grewal|title=Therapeutic targets of the TNF superfamily|url=http://books.google.com/books?id=GMr1VYauOt0C&pg=PA58|accessdate= |year=2009|publisher=Springer|isbn=9780387895192|pages=58–}} |
|||
* {{en}}{{cite book|author=Paul-Peter Tak|title=New Therapeutic Targets in Rheumatoid Arthritis|url=http://books.google.com/books?id=bF5RXbJ-nNkC&pg=PA14|accessdate |date=April 2009|publisher=Springer|isbn=9783764382377|pages=14–}} |
|||
* {{en}}{{cite book|author1=Michael H. Weisman|author2=Michael E. Weinblatt|author3=James S. Louie|coauthors=Ronald Van Vollenhoven|title=Targeted treatment of the rheumatic diseases|url=http://books.google.com/books?id=1yOLTwoEr4kC&pg=PA118|accessdate= |date=2 October 2009|publisher=Elsevier Health Sciences|isbn=9781416099932|pages=118–}} |
|||
* {{en}}{{cite book|author=Michael Hertl|title=Autoimmune Diseases of the Skin: Pathogenesis, Diagnosis, Management|url=http://books.google.com/books?id=meZcUs3Ry1UC&pg=PA546|accessdate= |date=November 2009|publisher=Springer|isbn=9783211992241|pages=546–}} |
|||
{{Portale|medicina}} |
{{Portale|medicina}} |
||
Versione delle 11:54, 27 mar 2011
Il belimumab (nome commerciale Benlysta, prima noto come LymphoStat-B ), nato dalla collaborazione fra Human Genome Sciences (HGS) e GlaxoSmithKline (GSK)[senza fonte], è un anticorpo monoclonale completamente umano che inibisce lo stimolatore dei linfociti B (BLyS), note anche come cellule B, inibendo il fattore di attivazione del TNF famiglia (BAFF).[1]
Si tratta di un farmaco approvato negli Stati Uniti per il trattamento del lupus eritematoso sistemico (LES), ed è in studio per altre malattie autoimmuni.
BLyS (o stimolatore dei linfociti B), è una proteina prodotta naturalemnte che è stato scoperta nel 1997 dai ricercatori della Human Genome Sciences, mentre il suo meccanismo è fisiologico stato descritto nel 1999.[2] La BLyS gioca un ruolo chiave nella differenziazione dei linfociti B, la loro sopravvivenza e l'attivazione.[3]
Il Benlysta è stato approvato dalla US Food and Drug Administration (FDA) per il trattamento del LES il 9 marzo 2011. Il comitato consultivo della FDA ha approvato la terapia, nonostante il farmaco ha mostrato di essere solo marginalmente efficace; ed inoltrem non è stato testato nelle forme gravi di lupus eritematoso sistemico, che coinvolgo attivamente i reni o il sistema nervoso centrale.[4]
Note
- ^ Bossen C, Schneider P, BAFF, APRIL and their receptors: structure, function and signaling, in Semin. Immunol., vol. 18, n. 5, October 2006, pp. 263–75, DOI:10.1016/j.smim.2006.04.006.
- ^ BLyS: member of the tumor necrosis factor family and B-lymphocyte stimulator. Moore PA, Belvedere O, Orr A, et al. Science. July 1999; 285: 260-263.
- ^ Crowley JE, Treml LS, Stadanlick JE, Carpenter E, Cancro MP, Homeostatic niche specification among naïve and activated B cells: a growing role for the BLyS family of receptors and ligands, in Semin. Immunol., vol. 17, n. 3, 2005, pp. 193–9, DOI:10.1016/j.smim.2005.02.001.
- ^ F.D.A. Approves Benlysta, a New Lupus Drug, By ANDREW POLLACK, New York Times, March 9, 2011
Bibliografia
- Frank Ashall, Le grandi scoperte scientifiche, Armando Editore, 1999, pp. 245–, ISBN 9788871449494.
- Immunologia cellulare e molecolare, Elsevier srl, 2010, pp. 79–, ISBN 9788821431760.
- Le basi dell'immunologia, Elsevier srl, 2006, pp. 70–, ISBN 9788885675858.
- Farmacologia, Elsevier srl, 2008, pp. 778–, ISBN 9788821430237.
- Enzo Fagiolo, Immunoematologia, Mediserve s.r.l., 2007, pp. 16–, ISBN 9788882041359.
- Paolo Larizza, Trattato di medicina interna, PICCIN, 2005, pp. 909–, ISBN 9788829917211.
- Angelo Sghirlanzoni, Terapia Delle Malattie Neurologiche, Springer, 3 April 2010, pp. 113–, ISBN 9788847011199.
- Thomas C. King, Patologia, Elsevier srl, 2008, pp. 156–, ISBN 9788821430190.
- (EN) Marie A. Simmons, Monoclonal antibodies: new research, Nova Publishers, 2005, ISBN 9781594542473.
- (EN) Zhiqiang An, Therapeutic Monoclonal Antibodies: From Bench to Clinic, John Wiley and Sons, 8 September 2009, ISBN 9780470117910.
- (EN) James W. Goding, Monoclonal antibodies: principles and practice : production and application of monoclonal antibodies in cell biology, biochemistry and immunology, Academic Press, 1996, ISBN 9780122870231.
- (EN) Steve Shire, Current Trends in Monoclonal Antibody Development and Manufacturing, Springer, April 2009, ISBN 9780387766423.
Belimumab
- (EN) Michael P. Cancro, BLyS Ligands and Receptors, Springer, 2010, pp. 178–, ISBN 9781603270120.
- (EN) Iqbal S. Grewal, Therapeutic targets of the TNF superfamily, Springer, 2009, pp. 58–, ISBN 9780387895192.
- (EN) Paul-Peter Tak, New Therapeutic Targets in Rheumatoid Arthritis, Springer, April 2009, pp. 14–, ISBN 9783764382377.
- (EN) Ronald Van Vollenhoven, Targeted treatment of the rheumatic diseases, Elsevier Health Sciences, 2 October 2009, pp. 118–, ISBN 9781416099932.
- (EN) Michael Hertl, Autoimmune Diseases of the Skin: Pathogenesis, Diagnosis, Management, Springer, November 2009, pp. 546–, ISBN 9783211992241.
